Article info

Download PDFPDF

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
Free

Authors

  1. Correspondence to Dr Emanuel Della-Torre, Università Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy; dellatorre.emanuel{at}hsr.it; Professor Lorenzo Dagna, Università Vita-Salute San Raffaele, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132 Milan, Italy; dagna.lorenzo{at}unisr.it
View Full Text

Citation

Della-Torre E, Campochiaro C, Cavalli G SARI-RAF Study Group, et al
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study

Publication history

  • Received May 28, 2020
  • Revised June 14, 2020
  • Accepted June 16, 2020
  • First published July 3, 2020.
Online issue publication 
September 14, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.